Ambergen
Company Details
Status: Private
Employees: 11-50
Location:
Watertown, Massachusetts, United States
Type:
sample
Technology:
sample
sample
About: AmberGen® is a biotechnology company and producer of Miralys™ spatial biology imaging solutions.
Miralys™, also known as MALDI HiPLEX-IHC, is a new breakthrough method for targeted intact protein imaging that has unique multimodal imaging capabilities. First introduced in 2022, it has gained significant traction, including 8 of the top 10 pharma companies, as well as many of the world's premier research institutions. It is currently being used to study tissues for a wide range of diseases including cancers, Alzheimer's and Parkinson's diseases; and even COVID.
Benefits include:
- Drug/target co-localization on the same sample, same instrument
- The ability to produce images that co-register small molecule lipids and metabolites as well as the intact targeted proteins.
- The product's combination of fast, targeted, protein imaging (scan time as short as 45 min and 1cm2), ultra-high plex (10 to 100+), wide viewing area (up to 25 x 75 mm), and multi-modal capability make it an ideal technology for doing initial scans to identify regions of interest for later deep-dive analysis.
- Miralys™ requires no dedicated instrument, and minimal investment to start using. It is used on MALDI Mass Spec Imaging instruments that your institution most likely already owns, such as the industry-leading instruments from our partner, Bruker Corporation.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Ambergen | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.